文献速递新发突发、热带与寄生虫病

青蒿素类似物三联疗法治疗肯尼亚儿童无并发症恶性疟:非劣效随机试验

Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
PubMed 文献 · Lancet Infect Dis · 2021-06-07

该单中心、开放标签、随机、非劣效试验在肯尼亚儿童中比较arterolane-piperaquine-mefloquine三联疗法与arterolane-piperaquine及artemether-lumefantrine的疗效与安全性。主要终点42天PCR校正有效率三联疗法为100%(72/72),非劣于artemether-lumefantrine的96%(69/72;风险差4%,95%CI 0-9;三联疗法安全,但给药后1小时内呕吐率高于artemether-lumefantrine。

要点

  • 三联疗法42天PCR校正有效率达100%,非劣于artemether-lumefantrine。
  • 三联疗法呕吐率5%,显著高于artemether-lumefantrine的1%。
  • 三联疗法可能用于预防或延缓抗疟药耐药。

核心结论

  • arterolane-piperaquine-mefloquine对肯尼亚儿童无并发症恶性疟有效且安全,可能用于预防或延缓抗疟药耐药。

研究设计与样本

  • 单中心、开放标签、随机、非劣效试验,在肯尼亚Kilifi县医院纳入2-12岁、 asexual parasitaemia 5000-250 000/μL的儿童。
  • 217名儿童随机分配至arterolane-piperaquine(n=73)、arterolane-piperaquine-mefloquine(n=72)或artemether-lumefantrine(n=72),纳入意向性治疗分析。
  • 非劣效界值为风险差-7%,主要终点为42天PCR校正有效率。

主要发现

  • arterolane-piperaquine-mefloquine与arterolane-piperaquine的42天PCR校正有效率风险差为0%。
  • 最常见不良事件为上呼吸道症状(artemether-lumefantrine组n=26;三联疗法组n=19;arterolane-piperaquine组n=23)、头痛(n=13;n=4;n=5)和腹痛(n=7;n=5;n=5),无死亡。

关键数值与推荐

  • 非劣效界值:风险差-7%。
  • arterolane-piperaquine-mefloquine vs arterolane-piperaquine风险差0%。

临床怎么用

  • 对于肯尼亚儿童无并发症恶性疟,arterolane-piperaquine-mefloquine可作为有效且安全的治疗选择。
  • 使用该三联疗法时需注意给药后1小时内呕吐率较高,必要时考虑补服。

局限性

  • 单中心、开放标签设计,患者、家长、临床人员及统计师未设盲。
  • 样本量较小(217例),仅纳入肯尼亚2-12岁儿童。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triple antimalarial combination therapies combine potent and rapidly cleared artemisinins or related synthetic ozonides, such as arterolane, with two, more slowly eliminated partner drugs to reduce the risk of resistance. We aimed to assess the safety, tolerability, and efficacy of arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Kenyan children. METHODS: In this single-centre, open-label, randomised, non-inferiority trial done in Kilifi County Hospital, Kilifi, coastal Kenya, children with uncomplicated Plasmodium falciparum malaria were recruited. Eligible patients were aged 2-12 years and had an asexual parasitaemia of 5000-250 000 parasites per μL. The exclusion criteria included the presence of an acute illness other than malaria, the inability to tolerate oral medications, treatment with an artemisinin derivative in the previous 7 days, a known hypersensitivity or contraindication to any of the study drugs, and a QT interval corrected for heart rate (QTc interval) longer than 450 ms. Patients were randomly assigned (1:1:1), by use of blocks of six, nine, and 12, and opaque, sealed, and sequentially numbered envelopes, to receive either arterolane-piperaquine, arterolane-piperaquine-mefloquine, or artemether-lumefantrine. Laboratory staff, but not the patients, the patients' parents or caregivers, clinical or medical officers, nurses, or trial statistician, were masked to the intervention groups. For 3 days, oral artemether-lumefantrine was administered twice daily (target dose 5-24 mg/kg of bodyweight of artemether and 29-144 mg/kg of bodyweight of lumefantrine), and oral arterolane-piperaquine (arterolane dose 4 mg/kg of bodyweight; piperaquine dose 20 mg/kg of bodyweight) and oral arterolane-piperaquine-mefloquine (mefloquine dose 8 mg/kg of bodyweight) were administered once daily. All patients received 0·25 mg/kg of bodyweight of oral primaquine at hour 24. All patients were admitted to Kilifi County Hospital for at least 3 consecutive days and followed up at day 7 and, thereafter, weekly for up to 42 days. The primary endpoint was 42-day PCR-corrected efficacy, defined as the absence of treatment failure in the first 42 days post-treatment, of arterolane-piperaquine-mefloquine versus artemether-lumefantrine, and, along with safety, was analysed in the intention-to-treat population, which comprised all patients who received at least one dose of a study drug. The 42-day PCR-corrected efficacy of arterolane-piperaquine-mefloquine versus arterolane-piperaquine was an important secondary endpoint and was also analysed in the intention-to-treat population. The non-inferiority margin for the risk difference between treatments was -7%. The study is registered in ClinicalTrials.gov, NCT03452475, and is completed. FINDINGS: Between March 7, 2018, and May 2, 2019, 533 children with P falciparum were screened, of whom 217 were randomly assigned to receive either arterolane-piperaquine (n=73), arterolane-piperaquine-mefloquine (n=72), or artemether-lumefantrine (n=72) and comprised the intention-to-treat population. The 42-day PCR-corrected efficacy after treatment with arterolane-piperaquine-mefloquine (100%, 95% CI 95-100; 72/72) was non-inferior to that after treatment with artemether-lumefantrine (96%, 95% CI 88-99; 69/72; risk difference 4%, 95% CI 0-9; p=0·25). The 42-day PCR-corrected efficacy of arterolane-piperaquine-mefloquine was non-inferior to that of arterolane-piperaquine (100%, 95% CI 95-100; 73/73; risk difference 0%). Vomiting rates in the first hour post-drug administration were significantly higher in patients treated with arterolane-piperaquine (5%, 95% CI 2-9; ten of 203 drug administrations; p=0·0013) or arterolane-piperaquine-mefloquine (5%, 3-9; 11 of 209 drug administrations; p=0·0006) than in patients treated with artemether-lumefantrine (1%, 0-2; three of 415 drug administrations). Upper respiratory tract complaints (n=26 for artemether-lumefantrine; n=19 for arterolane-piperaquine-mefloquine; n=23 for arterolane-piperaquine), headache (n=13; n=4; n=5), and abdominal pain (n=7; n=5; n=5) were the most frequently reported adverse events. There were no deaths. INTERPRETATION: This study shows that arterolane-piperaquine-mefloquine is an efficacious and safe treatment for uncomplicated falciparum malaria in children and could potentially be used to prevent or delay the emergence of antimalarial resistance. FUNDING: UK Department for International Development, The Wellcome Trust, The Bill & Melinda Gates Foundation, Sun Pharmaceutical Industries.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hamaluba M, van der Pluijm RW, Weya J, et al. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2021. PMID: 34111412. doi:10.1016/S1473-3099(20)30929-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。